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Abstract Amyotrophic lateral sclerosis (ALS) is a fatal
progressive neurodegenerative disease characterized by the
selective death of motor neurons in the motor cortex, brain
stem and spinal cord. Recently, missense variants in the
angiogenin gene (ANG), an angiogenic factor expressed in
ventral horn motor neurons that is up-regulated by
hypoxia, have been found in ALS patients of Irish/Scottish,
North American, Italian, French and Dutch descent. To
investigate the role of ANG in the German population, we
screened for mutations by sequencing the entire coding
region of the ANG gene in a large sample of 581 German
ALS cases and 616 sex- and age-matched healthy con-
trols. We identiﬁed two heterozygous missense variants,
F(-13)L and K54E, in two German sporadic ALS cases
but not in controls. Both missense variants are novel and
have not been previously found in ALS cases. Our results
suggest that missense variants in the ANG gene play a role
in ALS in the German population and provide further
evidence to support the hypothesis that angiogenic factors
up-regulated by hypoxia are involved in the pathophysi-
ology of ALS.
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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease that speciﬁcally affects the motor neurons in the
spinal cord, brain stem and motor cortex. To date, ﬁve ALS
causative genes have been identiﬁed in patients with
familial ALS, accounting for 5–10% of all ALS cases.
While autosomal dominant mutations in the Cu/Zn super-
oxide dismutase (SOD1)[ 20], vesicle-associated protein B
(VAPB)[ 17], and dynactin [19] have been shown to cause
adult-onset forms of ALS, mutations in senataxin (SETX)
lead to an early onset of the disease [3]. In contrast,
mutations in the gene encoding alsin have been associated
with juvenile-onset autosomal recessive ALS [10, 24].
In addition, genetic variants in certain genes may play a
role in modifying ALS susceptibility. Certain haplotypes in
the vascular endothelial growth factor (VEGF) gene have
been reported to be a possible risk factor for sporadic ALS
[16] in a population based study, whereas a recent meta-
analysis has conﬁrmed increased susceptibility for ALS in
male carriers of the promoter single nucleotide polymor-
phism (SNP) -2578AA [15]. Subsequently, seven mis-
sense variants in angiogenin (ANG), another angiogenic
factor in the ventral horn motor neurons which is up-reg-
ulated by hypoxia, have been suggested to be associated
with ALS in Irish/Scottish patients [9]. Other ANG mis-
sense variants have been identiﬁed in ALS patients from
North America [23], Italy [4, 7], France [18] and the
Netherlands [22]. In addition, recent functional studies
have shown that ANG missense variants identiﬁed in ALS
patients lead to reduced angiogenic activity of ANG in
endothelial cells [23], and impairment of neurite extension
and survival in motor neurons [14, 21].
To investigate the role of ANG in ALS patients from
Germany, we screened for mutations by sequencing the
entire coding region of the ANG gene in a large cohort of
German ALS patients and controls. We identiﬁed two
novel heterozygous ANG missense variants in two sporadic
ALS cases but not in controls. Our ﬁndings suggest that
missense variants in the ANG gene play a role in ALS in
the German population.
Subjects and methods
Subjects
Informed consent was obtained from 581 sporadic ALS
patients and 616 healthy controls. Of these, 401 patients
were referred to the Neurology Department of the Uni-
versity Hospital of Ulm, and 180 patients to the Neurology
Department of the University Hospital Grosshadern
(Munich). Samples from 365 age- and gender-matched
healthy controls were obtained from the adult population-
based KORA study [13], whereas those from 251 gender-
matched controls older than age 60 were obtained from our
local DNA database. The ALS sample consisted of 581
sporadic ALS patients with clinical diagnosis of probable
or deﬁnite ALS according to the revised El Escorial criteria
[1, 2]. The male to female ratio was 1.7. Average age-at-
onset was 59 years and average survival time was
51 months. 70% of the patients had limb onset, 30%
showed bulbar onset.
Genetic analysis
Genomic DNA was isolated from peripheral blood using
standard protocols. The GenBank reference sequence
accession number of ANG was NM_001145.4. In the
cDNA, the A of the ATG translation initiation start site was
numbered as nucleotide ?1. In accordance with the liter-
ature, amino acids from the signal peptide of ANG (24
aminoacids) were named in negative numbers whereas
those from the processed protein (123 amino acids) were
named in positive numbers, the ﬁrst Gln residue of the
entire sequence being numbered as amino acid ?1. Primers
were designed using the ExonPrimer software (http://
ihg.gsf.de/ihg/ExonPrimer.html) for the ANG coding
region. PCR products were sequenced directly using the
BigDye Terminator Cycle sequencing kit 3.1 (Applied
Biosystems) and were analyzed on an ABI3730 sequencer.
The following primers were used for PCR and sequencing:
50-TGTTCTTGGGTCTACCACACC-30,5 0-ATGTTGCCA
CCACTGTTCTG-30 (amplicon length: 583 bp). The
complete ANG coding region was sequenced for both case
and control subjects from forward and reverse ends
including the exon/intron junction.
Statistical analysis
The statistical analysis of the allelic frequency for SNP
rs11701 was conducted using the v
2 test with one degree of
freedom.
Bioinformatics
Missense variants were mapped onto the three-dimensional
crystal structure of the mature ANG protein using PyMOL
software (Delano Scientiﬁc LLC).
Results
In our study, we identiﬁed two heterozygous ANG mis-
sense variants in two ALS patients of German descent that
were negative for mutations in the SOD1 screening
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123(Table 1). A ca. 36 C[T transition located within the signal
peptide of ANG results in a F(-13)L substitution whereas
the ca. 232 A[G transition causes a K54E amino acid
substitution that affects the mature protein. The replace-
ment of the basic Lys by the acid Glu in K54E is repre-
sented in Fig. 1. The missense variants F(-13)L and K54E
are novel and have not been previously linked to ALS.
Neither of these variants were found in 616 controls.
Overall, the estimated mutational frequency of the ANG
gene is 0.3% in our population. Unfortunately, the segre-
gation of missense variants F(-13)L and K54E could not
be investigated further due to the unavailability of DNA
from family members of the patients. However, none of the
carriers had a familial history of ALS. The clinical picture
of the F(-13)L and K54E carriers is summarized in
Table 1.
Our results also identiﬁed the previously reported het-
erozygous missense variant I46V (ca. 208 A[G) in one
ALS patient but not in controls. Originally, I46V was
described in three Scottish ALS patients [9] and subse-
quently in two French cases [18]. Nonetheless, I46V has
been suggested to be a benign variant, at least in the Italian
population, because it was found in a total of 7 Italian
patients and 11 healthy controls [4, 5, 7]. Furthermore, we
identiﬁed the variant K17I (ca. 122 A[T) in one sporadic
ALS case (0.1%) and two controls (35/62 years of age)
(0.3%). This ﬁnding is in agreement with a previous study
that identiﬁed K17I in two Irish/Scottish ALS patients and
one control (65 years) [9]. In a Dutch pedigree, variant
K17I was recently shown to segregate with disease fol-
lowing an autosomal dominant inheritance model with
reduced penetrance [22]. Of the 17 different ANG missense
variants identiﬁed in ALS patients up to date (Table 1,
supplemental data), only K17I and I46V were found in
both cases and controls.
Examination of ANG evolutionary conservation showed
that residues Phe(-13), Lys17, Ile46 and Lys54 are con-
served in mammals (Fig. 1, supplemental data). None of
the identiﬁed missense variants were exclusively present in
controls.
The sequence analysis conﬁrmed the presence of the
common synonymous SNP rs11701 (T/G) in our popula-
tion. This SNP was shown to be associated with ALS in the
Irish population [9] in which the frequency of the allele G
was signiﬁcantly higher in ALS cases compared with
controls (0.17 vs. 0.09, P\0.001). Nevertheless, we did
not ﬁnd the association of this allele to disease as previ-
ously reported in the Irish/Scottish population (Table 2). In
our sample, the distribution of the G allele was 0.12 in
cases and 0.13 in controls (P[0.05). The previously
identiﬁed SNP rs17560 was not observed in our sample.
However, we found the allele T of the SNP rs2228653 in
one ALS case and none of the controls. This SNP is located
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123within the coding region of ANG and results in the syn-
onymous substitution T97T, which makes it difﬁcult to
predict whether this synonymous variant is disease speciﬁc.
Discussion
ANG was ﬁrst suggested to be a susceptibility gene for
ALS when the SNP rs11701, located within the coding
region of the gene, was found to be signiﬁcantly associated
with disease in an Irish ALS cohort [8]. Subsequently,
seven different heterozygous ANG missense variants were
identiﬁed in a large cohort of 1629 patients from Ireland,
Great Britain, the USA and Sweden [9]. Although ANG
missense variants were present in individuals from all four
subpopulations, the majority of the affected individuals
were of Irish/Scottish descent, suggesting that ANG might
be a speciﬁc ALS susceptibility factor in the Irish/Scottish
subpopulation. However, another study conﬁrmed the
occurrence of ANG missense variants in an independent
ALS cohort of North American descent [23]. Subsequently,
novel ALS-associated ANG missense variants were repor-
ted in one French [18], one Dutch [22] and two different
Italian [4, 7] samples. In contrast, two additional Italian
groups have failed to identify ANG missense variants in
their ALS cohorts [5, 6]. To date, no report has assessed the
role of ANG in the German ALS population.
In our study, we sequenced the coding region of the
ANG gene in a German ALS cohort and in controls. Our
sample, together with that of Gellera et al. [7], is the second
largest sample studied after the one from Greenway et al.
[9]. We identiﬁed two ANG missense variants, F(-13)L
and K54E, in two ALS cases (0.3%; 2/581). Both ANG
missense variants are novel and, to our knowledge, have
not been previously documented. The variants F(-13)L
and K54E appear to be disease-speciﬁc in our population,
since both were absent in our 616 controls, as well as in
3107 controls that were sequenced in previous ANG
mutational screenings [4–7, 9, 18, 22, 23]. Our results
indicate that the novel ANG missense variants F(-13)L
and K54E are linked to ALS in the German population.
In the Scottish/Irish population, several ANG missense
variants have been suggested to segregate with familial and
sporadic ALS [9]. However, segregation of ANG missense
variants has not been fully reproduced in other populations
[5, 7, 18, 23] until the recent screening of a Dutch pedigree
carrying the K17I missense variant [22]. In our case, the
carriers of the ANG missense variants F(-13)L and K54E
were apparently ‘sporadic’ ALS cases without a family
history of ALS. Both mutation carriers were male patients
with predominant lower motor-neuron deﬁcits and a
reduced life expectancy of less than 3 years. The F(-13)L
carrier had a late age at onset (71 years), while the K54E
carrier showed an early onset of disease (28 years). Inter-
estingly, the K54E carrier showed clear signs of frontal
deﬁcit. Nonetheless, because the K54E carrier was
deceased, we were unable to further characterize this
patient clinically. Previously, a Dutch patient carrying the
missense variant K17I presented ALS with frontotemporal
dementia (FTD) [22], whereas another Italian SALS patient
with a synonymous ca. 132 C[T variant had a diagnosis of
frontal lobe dysfunction [7]. These ﬁndings are interesting
because they suggest that ANG may also be involved in
cognitive impairment.
F(-13)L is located in the signal peptide of ANG,
whereas K54E affects the mature ANG protein. Although
the effects of these missense variants on the ANG protein
are difﬁcult to predict, we performed structural modeling of
these variants in the 3-D crystal structure of the protein.
We speculate that the F(-13)L variant, located in the
signal peptide of ANG which is involved in protein traf-
ﬁcking [12], might lead to abnormal protein transport and
secretion or toan altered recognition site for the signal
peptide peptidase, leading to mislocalization of ANG. In
the case of the K54E variant, the replacement of a basic
residue by an acidic glutamate disrupts a patch of posi-
tively charged protein surface formed by residues Lys50,
Table 2 Genotypic and allelic frequencies of synonymous SNP
rs11701 in German ALS patients and controls
Patients Controls
TT genotype 0.768 0.747
TG genotype 0.217 0.235
GG genotype 0.015 0.018 (P[0.05)
T allele 0.876 0.864
G allele 0.124 0.136 (P[0.05)
Fig. 1 Structure of angiogenin (PDB-ID 1h53). a, b Angiogenin is
shown as ribbons with the phosphate near the active site and with the
mutated residue shown as sticks. The K54 side-chain from the wild-
type protein is in blue (a), the modeled K54E side chain is in red (b)
1340 J Neurol (2009) 256:1337–1342
123Arg51 and Lys54 that might be of functional relevance for
the interaction of ANG with negatively charged molecules
like nucleic acids or other proteins.
To date, a total of 15 different ANG missense variants
have been exclusively identiﬁed in ALS patients but not in
controls [4, 7, 9, 18, 22, 23], including the novel ANG
missense variants F(-13)L and K54E reported in this
study. Altogether, these results clearly suggest that mis-
sense variants in the ANG gene, although rare, are poten-
tially causative of disease as recently suggested in
discussions regarding other complex neurodegenerative
diseases, including the glucocerebroside gene (GBA)i n
Parkinson’s disease (PD) [11].
There is increasing evidence that variants in the ANG
gene play a role in ALS pathophysiology. Recently, the
ANG missense variants K17I, S28N and P112L identiﬁed
in ALS patients from North America have been shown to
result in complete ANG loss-of-function by reducing
angiogenesis due to defects in ribonuclease activity,
nuclear translocation, or a combination of both [23]. In
addition, an independent study has shown that human ANG
is neuroprotective, whereas the ALS-associated ANG
variants Q12L, C39W and K40I, which are located in the
catalytic center of the protein, compromise neurite exten-
sion, pathﬁnding and survival of motor-neurons [14, 21].
These ﬁndings have been conﬁrmed for K40I in another
recent report [14]. Furthermore, ANG is highly expressed
in the spinal cord ventral horn motor-neurons during both
fetal development and adulthood [21].
In summary, we identiﬁed two heterozygous missense
variants, F(-13)L and K54E, in the ANG gene of two
sporadic ALS patients of German descent but not in con-
trols. Our results suggest that the F(-13) and K54E ANG
missense variants are linked to ALS in the German popu-
lation and support the hypothesis that angiogenic factors
up-regulated by hypoxia are involved in the pathophysi-
ology of ALS. Future functional studies will help to deci-
pher the speciﬁc role of these ANG missense variants in
ALS.
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